BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

GVHD

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD).

KiadisMAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, the company is developing T cell therapies to make bone marrow transplantations safer and more effective.

The Biotech’s lead candidate, ATIR101 is a T-cell immunotherapy that eliminates alloreactive cells from the donor to minimize the risk of GVHD after hematopoietic stem cell transplantation (HSCT), currently the most effective treatment for most blood cancers. The therapy has completed a pivotal Phase II study and is currently being investigated in Phase III for blood cancers in adults. With its innovative therapy, Kiadis is pioneering the field by going for a major issue in HSCT.


Images via shutterstock.com / angellodeco

Previous post

Infographic: Who's who in the mRNA Therapeutics Field in Europe?

Next post

BRIEF: Galapagos and Gilead add Lupus to their Growing List of Indications

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.